Welcome to our dedicated page for Apollomics SEC filings (Ticker: APLMW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Apollomics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Apollomics's regulatory disclosures and financial reporting.
Apollomics Inc. (APLM) director Huang Ya-Chi reported the vesting and settlement of 500 Restricted Stock Units, each representing a contingent right to receive one Class A Ordinary Share. On August 17, 2026, these RSUs were exercised into 500 Class A Ordinary Shares at a reported price of $0.00 per share, increasing the director’s direct holdings to 1,500 Class A Ordinary Shares. Footnotes state the RSU award vests in four equal 500-share tranches on February 17, May 17, August 17, and November 17, 2026, with this transaction reflecting the August vesting.
Apollomics Inc. insider Yi-Kuei Chen, its Chief Operating Officer and director, reported an indirect purchase of 20,000 Class A ordinary shares of APLM on August 14, 2026 at $15.00 per share, acquired through a private placement transaction by Maxpro Investment Co., Ltd. Following this acquisition, indirect holdings through Maxpro Investment Co., Ltd. are reported as 121,248 shares, and a separate direct holding position of 15,000 shares is reported. The filing notes that Chen is a board member of Maxpro Investment Co., Ltd. and co-founder and managing director of Maxpro Ventures Ltd., and disclaims beneficial ownership of the Maxpro-held securities except to the extent of his pecuniary interest.
Apollomics Inc. executive Peter Kuan-How Lin, the Chief Financial Officer, purchased 26,667 Class A Ordinary Shares of APLM on August 14, 2026 at $15.00 per share. The shares were acquired pursuant to a private placement transaction referenced in a Form 6-K filed on August 12, 2026. Following this transaction, Lin directly holds 48,979 Class A Ordinary Shares.
Apollomics Inc. reported that Chief Executive Officer Hung-Wen Chen purchased a total of 536,667 Class A ordinary shares on August 14, 2026. The purchases, described as acquired pursuant to a private placement, included 166,667 shares at $12.00 per share and 103,333 shares at $15.00 per share held directly, and 266,667 shares at $15.00 per share held indirectly through King Regent Management Limited. Following the transaction, King Regent Management Limited held 1,029,695 shares, over which Mr. Chen has voting and dispositive power while disclaiming beneficial ownership beyond his pecuniary interest.
Apollomics Inc. reported that its Chairman and Chief Executive Officer, Hung‑Wen (Howard) Chen, together with his wholly owned vehicle King Regent Management Limited, completed a PIPE and note conversion on August 14, 2026. Mr. Chen and King Regent acquired an aggregate of 370,000 Class A ordinary shares for $5,550,005.00 in cash and through conversion of a convertible promissory note.
Following these transactions and recent RSU vesting, Mr. Chen beneficially owns 1,453,029 Class A shares, or 49.76% of the outstanding Class A shares, including 1,029,695 shares held through King Regent. The ownership percentage is based on 2,919,962 shares deemed outstanding under Rule 13d‑3(d)(1).
Apollomics Inc. disclosed an update on the holdings of investor Yi‑Kuei (Alex) Chen. An affiliated entity, Maxpro Investment Co., Ltd., entered into a Subscription Agreement on August 7, 2026 to purchase 20,000 Class A shares at $15.00 per share, for an aggregate purchase price of $300,000, in a private placement that closed on August 14, 2026.
Following this transaction, Mr. Chen beneficially owns 145,171 Class A shares, including shares held directly, RSUs vesting within 60 days, and warrants held by Maxpro, representing approximately 4.97% of the company’s Class A shares deemed outstanding for reporting purposes. Because the total number of outstanding Class A shares increased after the private placement, Mr. Chen ceased to be the beneficial owner of more than five percent of the class on August 14, 2026. The newly issued shares are restricted securities subject to transfer limitations under the Subscription Agreement.
Apollomics Inc. director Yen Hung Hsien reported initial beneficial ownership of 500 restricted stock units linked to Class A Ordinary Shares. The RSUs were granted on July 20, 2026 and will vest on September 15, 2026, each converting into one share, subject to continued employment. The report is connected to the Holding Foreign Insiders Accountable Act.
Apollomics Inc. reports that Nasdaq has confirmed the company has regained compliance with the Market Value of Listed Securities (MVLS) requirement under Nasdaq Listing Rule 5550(b)(2) for continued listing on the Nasdaq Capital Market.
Nasdaq staff determined that from June 23, 2026 to July 7, 2026 Apollomics’ MVLS was $35 million or greater for 10 consecutive business days, following an earlier June 18, 2026 notice of non-compliance when MVLS had been below the required $35 million minimum for 30 consecutive business days. The matter is now closed. Apollomics is a late-stage clinical biopharmaceutical company whose lead program, vebreltinib (APL-101), is in a Phase 2 multicohort trial for cancers with c-Met alterations.
Apollomics Inc. reported that Nasdaq has notified the company it no longer meets the required Market Value of Listed Securities (MVLS) of $35 million for continued listing on The Nasdaq Capital Market. Apollomics has 180 days, until December 15, 2026, to restore compliance, and its shares continue trading under the symbol APLM during this period.
Separately, Apollomics terminated its Collaboration and License Agreement with Launxp International after Launxp failed to pay the remaining $3.8 million upfront balance plus interest. All licenses granted to Launxp ended immediately, and Apollomics has begun the contractually required dispute resolution process while seeking recovery of the unpaid amount. The company has regained rights to its lead drug candidate vebreltinib (APL‑101) across Asia, now holding global rights outside Mainland China and Macau.
Apollomics Inc. Chief Financial Officer Peter Kuan-How Lin reported routine equity compensation activity involving restricted stock units (RSUs). On June 15, 2026, 10,000 RSUs vested into Class A Ordinary Shares, reflecting previously granted awards that vest in four 10,000-share installments.
In connection with this vesting, 3,588 Class A Ordinary Shares were disposed of to cover tax obligations, a tax-withholding disposition rather than an open-market sale. After these transactions, Lin held 22,312 Class A Ordinary Shares directly. The filing reflects compensation-related equity settlement, not a discretionary market purchase or sale.